(A) Effect of NO/cGMP on Ucp1 and Prdm16 mRNA levels in the treated PPCs with combination of SNP and BMP7 using the soluble guanylyl cyclase inhibitor, ODQ. (B&C) Effect of PKGIα activity (B) and Ucp1 mRNA expression (C) in the treated PPCs with SNP and BMP7 in the absence or presence of KT5823. (D) PKGIα activity is required to induce UCP1 expression in the PPCs by overexpressing adenoviral PKGIα as a gain of PKGIα function. (E) Tyrosine (216/279) and serine (9/21) phosphorylation of GSK3β in the PPC with combination of SNP and BMP7. (F) Synergistic effect of NO/cGMP and BMP7 signaling on differentiation of PPCs and UCP1 expression via tyrosine (216/279) phosphorylation of GSK3β using the GSK3β inhibitor, SB216763 in the PPCs. Biological replicates n=6 for each group. P values were determined by Two-way ANOVA with Tukey’s multiple comparisons test in E, and by Three-way ANOVA with Tukey’s multiple comparisons test in A, B, C, D and F. Data presented as mean ± SD; n=mice/group as indicated.